- Home
- BBIO vs TECH Comparison
BBIO vs TECH Comparison
Compare BBIO & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBIO
- TECH
- Stock Information
- Founded
- BBIO 2015
- TECH 1976
- Country
- BBIO United States
- TECH United States
- Employees
- BBIO N/A
- TECH N/A
- Industry
- BBIO Biotechnology: Pharmaceutical Preparations
- TECH Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BBIO Health Care
- TECH Health Care
- Exchange
- BBIO Nasdaq
- TECH Nasdaq
- Market Cap
- BBIO 9.4B
- TECH 8.2B
- IPO Year
- BBIO 2019
- TECH 1989
- Fundamental
- Price
- BBIO $55.32
- TECH $60.60
- Analyst Decision
- BBIO Strong Buy
- TECH Buy
- Analyst Count
- BBIO 16
- TECH 12
- Target Price
- BBIO $64.44
- TECH $70.64
- AVG Volume (30 Days)
- BBIO 2.0M
- TECH 2.9M
- Earning Date
- BBIO 11-11-2025
- TECH 10-29-2025
- Dividend Yield
- BBIO N/A
- TECH 0.53%
- EPS Growth
- BBIO N/A
- TECH N/A
- EPS
- BBIO N/A
- TECH 0.46
- Revenue
- BBIO $235,812,000.00
- TECH $1,219,635,000.00
- Revenue This Year
- BBIO $115.46
- TECH $3.97
- Revenue Next Year
- BBIO $65.03
- TECH $7.81
- P/E Ratio
- BBIO N/A
- TECH $131.65
- Revenue Growth
- BBIO 7.62
- TECH 5.23
- 52 Week Low
- BBIO $21.72
- TECH $46.01
- 52 Week High
- BBIO $55.32
- TECH $80.80
- Technical
- Relative Strength Index (RSI)
- BBIO 59.91
- TECH 59.12
- Support Level
- BBIO $52.97
- TECH $50.13
- Resistance Level
- BBIO $55.13
- TECH $63.23
- Average True Range (ATR)
- BBIO 1.58
- TECH 2.26
- MACD
- BBIO 0.16
- TECH 0.76
- Stochastic Oscillator
- BBIO 84.41
- TECH 65.25
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About TECH Bio-Techne Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.